J Gronwald
Overview
Explore the profile of J Gronwald including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
2906
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Millstein J, Budden T, Goode E, Anglesio M, Talhouk A, Intermaggio M, et al.
Ann Oncol
. 2020 May;
31(9):1240-1250.
PMID: 32473302
Background: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated...
2.
Metcalfe K, Lubinski J, Gronwald J, Huzarski T, McCuaig J, Lynch H, et al.
Clin Genet
. 2017 Dec;
93(5):1063-1068.
PMID: 29206279
The objective of this study was to estimate the lifetime risk of breast cancer in women with a BRCA1 or BRCA2 mutation with and without at least 1 first-degree relative...
3.
Lubinski J, Marciniak W, Muszynska M, Huzarski T, Gronwald J, Cybulski C, et al.
Breast Cancer Res Treat
. 2017 Oct;
167(2):591-598.
PMID: 29043463
Background: Studies have reported an inverse relationship between serum selenium levels and cancer incidence, but the impact of low serum selenium status on survival after a diagnosis of breast cancer...
4.
Menkiszak J, Sopik V, Chudecka-Glaz A, Domagala W, Urasinska E, Symonowicz H, et al.
Clin Genet
. 2016 Sep;
91(2):322-327.
PMID: 27623744
The aim of the study was to evaluate the impact of a regional population-based genetic testing program on the incidence of ovarian cancer in West Pomerania. Between 1999 and 2010,...
5.
Huzarski T, Byrski T, Gronwald J, Cybulski C, Oszurek O, Szwiec M, et al.
Breast Cancer Res Treat
. 2016 Mar;
156(2):371-8.
PMID: 26983446
The aim of the study is to identify treatments which predict survival for women with a BRCA1 mutation, including oophorectomy and chemotherapy. 476 women with stage I to stage III...
6.
Cybulski C, Lubinski J, Wokolorczyk D, Kuzniak W, Kashyap A, Sopik V, et al.
Clin Genet
. 2014 Oct;
88(4):366-70.
PMID: 25330149
A number of genes other than BRCA1 and BRCA2 have been associated with breast cancer predisposition, and extended genetic testing panels have been proposed. It is of interest to establish...
7.
Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, et al.
Breast Cancer Res Treat
. 2014 Aug;
147(2):401-5.
PMID: 25129345
The aim of this study is to estimate the frequency of pathologic complete response (pCR) after neoadjuvant treatment with cisplatin chemotherapy in women with breast cancer and a BRCA1 mutation....
8.
Huzarski T, Cybulski C, Wokolorczyk D, Jakubowska A, Byrski T, Gronwald J, et al.
Breast Cancer Res Treat
. 2014 Feb;
144(2):397-403.
PMID: 24557336
The purpose of this study is to estimate 10-year survival rates for patients with early onset breast cancer, with and without a CHEK2 mutation and to identify prognostic factors among...
9.
Szwiec M, Jakubowska A, Gorski B, Huzarski T, Tomiczek-Szwiec J, Gronwald J, et al.
Clin Genet
. 2014 Feb;
87(3):288-92.
PMID: 24528374
Three founder alleles of BRCA1 (C61G, 4153delA, 5382insC) were reported in Poland in 2000, and these three mutations have comprised the standard testing panel used throughout the country. However, since...
10.
Phelan C, Iqbal J, Lynch H, Lubinski J, Gronwald J, Moller P, et al.
Br J Cancer
. 2013 Dec;
110(2):530-4.
PMID: 24292448
Background: The BRCA1 and BRCA2 genes confer increased susceptibility to breast and ovarian cancer and to a spectrum of other cancers. There is controversy regarding the risk of colorectal cancer...